|
Christine Bulawa received a PhD in Biochemistry from the University of Wisconsin-Madison and was a postdoctoral fellow at the Massachusetts Institute of Technology. As the first employee of Myco Pharmaceuticals (later ChemGenics), Christine developed methods for target validation for the human pathogen Candida albicans that become a cornerstone of a partnership with Pfizer in the area of antifungal drug discovery. At Millennium Pharmaceuticals, Christine and her group applied genomic technologies to the Pfizer-Millennium Antifungal Program and successfully developed hit-to-target screening approaches and compound mechanism-of-action capabilities. In addition, Christine used yeast as a model system to advance targets and compounds in Millennium's Cardiovascular Biology, Metabolic Disease, Inflammation, and Oncology programs. | 